Literature DB >> 15946144

Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.

Wai Man Wong1, Jiaqing Huang, Harry H X Xia, Fiona M Y Fung, Teresa S M Tong, Kess L Cheung, Vicky Y K Ho, Kam Chuen Lai, Chi Kuen Chan, Annie O O Chan, Chee-Kin Hui, Shiu Kum Lam, Benjamin C Y Wong.   

Abstract

BACKGROUND: Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second-line treatment of Helicobacter pylori infection. The effects were compared of 7-day low-dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients.
METHODS: Helicobacter pylori-positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10) or (ii) high-dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by (13)c-urea breath test 5 weeks after stopping medications. side-effects of treatments were documented.
RESULTS: A total of 120 patients were eligible for analysis. By intention-to-treat and per-protocol analysis, the eradication rates were 83% and 86% in the RAM-10 group and 75% and 76% in the RAM-20 group, respectively (P = 0.26 and P = 0.17). Both regimens were well-tolerated and compliance was >98% in both groups.
CONCLUSIONS: Low-dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well-tolerated therapy for the treatment of H. pylori infection in Chinese population. (c) 2005 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946144     DOI: 10.1111/j.1440-1746.2005.03889.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  2 in total

1.  First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic.

Authors:  Gökhan Selçuk Özbalcı; Saim Savaş Yürüker; İsmail Alper Tarım; Hamza Çınar; Ayfer Kamalı Polat; Aysu Başak Özbalcı; Kağan Karabulut; Kenan Erzurumlu
Journal:  Ulus Cerrahi Derg       Date:  2014-09-01

2.  Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis.

Authors:  Wenwen Gao; Xiang Zhang; Yanhui Yin; Shuwen Yu; Lu Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.